查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1919334

經皮皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場按產品類型、便攜性、安裝方式和最終用戶分類 - 全球預測 2026-2032 年

Transcutaneous PO2 & PCO2 Monitor Market by Product Type, Portability, Mounting Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場價值為 5.1638 億美元，預計到 2026 年將成長至 5.6058 億美元，到 2032 年將達到 8.0369 億美元，複合年成長率為 6.52%。

關鍵市場統計數據
基準年 2025 5.1638億美元
預計年份：2026年 5.6058億美元
預測年份 2032 8.0369億美元
複合年成長率 (%) 6.52%

將經皮氧分壓和二氧化碳分壓監測策略性地應用於經皮發展的臨床工作流程和以患者為中心的呼吸護理路徑

經皮氧分壓和二氧化碳分壓監測是一項成熟且不斷發展的診斷技術，它將床邊生理狀態與更廣泛的醫療服務目標連結起來。本報告首先將經經皮氧分壓（PO2）和二氧化碳分壓（PCO2）監測置於現代臨床路徑中，其中連續、非侵入性的氣體評估支持新生兒穩定、重症監護協調、手術全期手術期管理和遠端呼吸追蹤。雖然脈搏血氧計和動脈血氣分析已成為某些診療標準，但經皮感測器具有互補的時間解析度和生理保真度，能夠減少有創採樣並實現更早的治療性介入。

技術、監管和醫療服務模式的變革如何融合，重新定義經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測的部署和價值

經經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測領域正因技術和架構的創新而改變。感測器化學的進步、更薄的薄膜設計以及低功耗無線通訊協定的出現，使得設備更加精準且易於部署。同時，軟體驅動的分析和雲端資料聚合正在拓展單一感測器資料的效用，使其能夠用於建立縱向患者記錄並提供人群層面的洞察。這些進步共同推動了新型醫療模式的形成，在這種模式下，持續的生理監測能夠實現早期療育和更個人化的治療調整。

評估 2025 年美國關稅如何重塑經經皮監測設備供應商的供應鏈、籌資策略和產品設計重點。

2025年美國關稅政策的變化對經皮監測的供應鏈和商業策略產生了多方面的影響。特別是，關稅影響了感測器組件、電子模組和成品的採購成本，促使製造商和醫療系統採購團隊重新評估其供應商佈局。因此，一些供應商正在加快供應商多元化進程，並增加對近岸生產能力的投資，以降低關稅風險並縮短前置作業時間。

深入了解經皮監測產品類型、便攜性、安裝方式和最終用戶環境如何驅動差異化需求和採用路徑

這項細分分析揭示了不同的臨床需求和部署環境如何影響經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測的產品開發和商業化重點。按產品類型分類，包括整合雙氣體檢測的組合式監測解決方案、針對二氧化碳趨勢最佳化的專用 PCO2 設備以及專注於氧氣評估的專用 PO2 系統。這些差異會影響校準策略、感測器膜的選擇以及臨床醫生在不同護理場景中優先考慮的使用者介面功能。

我們探討了區域差異，並解釋了為什麼美洲、歐洲、中東和非洲以及亞太市場都需要獨特的實施、分銷和支援策略。

區域趨勢在塑造經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測的產品需求、監管策略和市場推廣方式方面發揮著至關重要的作用。在美洲，許多醫療保健系統優先考慮基於價值的採購，並快速採用已被證實能夠減少侵入性手術的技術。這種環境有利於那些能夠與更廣泛的醫療保健 IT 生態系統整合，並提供可靠的臨床證據證明效用的設備。主要國內市場的法規結構也為臨床檢驗和醫院採用提供了一致的路徑，從而促進了供應商與大型綜合醫療保健網路之間的夥伴關係。

透過臨床檢驗、整合服務模式和數據驅動差異化，不斷演變經皮監測供應商之間的競爭定位

經經皮監測領域的競爭格局由眾多參與者構成，包括成熟的醫療設備製造商、專業感測器開發商和新興的數位醫療公司。主要企業憑藉其臨床檢驗的深度、強大的分銷網路以及將監測數據整合到更廣泛的醫療管理系統中的能力而脫穎而出。一些公司優先考慮垂直整合，透過控制感測器的化學成分、電子元件和軟體來最佳化性能並保護智慧財產權。另一些公司則透過建立策略聯盟和授權協議來加速市場進入並擴展產品系列。

為製造商和醫療系統提供實際的策略行動，以加速產品應用、降低價值鏈風險並展現臨床和經濟價值。

產業領導者若想加速產品普及並保障商業性利潤，應將產品開發、監管規劃和商業模式與實際臨床工作流程相契合。優先考慮互通性和以使用者為中心的設計，確保設備能夠整合到各種電子病歷環境中，並讓臨床醫生在接受培訓後即可輕鬆上手。投資於基於標準的通訊協定和簡化的使用者介面，將降低產品普及門檻，並有助於臨床醫生儘早接受產品。

透明、多維度的研究結合了臨床醫生訪談、供應商評估和監管分析，提供檢驗的、可操作的見解。

本分析的研究基礎是將與關鍵相關人員的直接對話與系統性的二手資料研究結合，從而得出嚴謹且切實可行的結論。主要資訊來源包括對新生兒科、重症監護室、急診部和手術全期手術期醫學等專科的臨床醫生；來自不同類型醫療系統的採購主管；以及醫療設備製造商和零件供應商的高管進行的深度訪談。這些訪談旨在揭示實際應用中的挑戰、臨床優先事項和採購決策標準，從而提供有助於解讀技術趨勢和競爭格局的見解。

本文對經皮監測相關人員而言，是一份簡明扼要的策略性結論，它將技術進步、供應鏈現狀和臨床重點連結起來。

總之，經皮氧分壓（PO2）和二氧化碳分壓（PCO2）監測在現代呼吸和重症監護實踐中發揮日益重要的作用。技術的進步、數據整合能力的提升以及以服務為導向的商業化模式，正在拓展這些設備發揮臨床價值的適用範圍。同時，供應鏈壓力和不斷變化的監管要求也迫使供應商和採購商採取穩健的籌資策略，並優先考慮高度互通性、以使用者為中心的解決方案。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場（按產品類型分類）

  • 複合監測器
  • PCO2監測
  • 氧分壓監測

第9章 行動端經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測市場

  • 攜帶式的
  • 固定式

第10章 依安裝方式經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場

  • 桌面型
  • 壁掛式

第11章經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場（以最終用戶分類）

  • 診所
    • 門診手術中心
    • 醫生診所
  • 居家醫療
  • 醫院
    • 急診室
    • 加護病房
    • 新生兒加護病房
    • 手術室

第12章經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國經經皮氧分壓 (PO2) 與二氧化碳分壓 (PCO2) 監測儀市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章美國經皮氧分壓 (PO2) 和二氧化碳分壓 (PCO2) 監測儀市場

16. 中國經皮氧分壓（PO2）及二氧化碳分壓（PCO2）監測儀市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bionet Co., Ltd.
  • Contec Medical Systems Co., Ltd.
  • Criticare Systems, Inc.
  • Dragerwerk AG & Co. KGaA
  • Edan Instruments, Inc.
  • Edwards Lifesciences Corporation
  • GE Healthcare Ltd.
  • Masimo Corporation
  • Medtronic plc
  • Mindray Medical International Limited
  • Natus Medical Incorporated
  • NIHON KOHDEN Corporation
  • Nonin Medical, Inc.
  • OSENSA Innovations, Inc.
  • Oximetrix, Inc.
  • Philips Healthcare
  • PULSION Medical Systems SE
  • Radiometer Medical ApS
  • SenTec AG
  • SLE Limited
  • Smiths Medical, Inc.
  • Spacelabs Healthcare, Inc.
  • Toshiba Medical Systems Corporation
Product Code: MRR-F14BA1B341C5

The Transcutaneous PO2 & PCO2 Monitor Market was valued at USD 516.38 million in 2025 and is projected to grow to USD 560.58 million in 2026, with a CAGR of 6.52%, reaching USD 803.69 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 516.38 million
Estimated Year [2026] USD 560.58 million
Forecast Year [2032] USD 803.69 million
CAGR (%) 6.52%

A strategic introduction that situates transcutaneous PO2 and PCO2 monitoring within evolving clinical workflows and patient-centered respiratory care pathways

Transcutaneous monitoring of partial pressures of oxygen and carbon dioxide represents a mature yet evolving diagnostic modality that bridges bedside physiology with broader care delivery objectives. This report opens by situating transcutaneous PO2 and PCO2 monitoring within modern clinical pathways, where continuous, noninvasive gas assessment supports neonatal stabilization, critical care titration, perioperative management, and remote respiratory follow-up. Where pulse oximetry and arterial blood gas sampling have defined certain standards of care, transcutaneous sensors offer complementary temporal resolution and physiologic fidelity that can reduce invasive sampling and enable earlier therapeutic intervention.

As clinical teams confront staffing constraints, heightened demand for neonatal and critical care services, and an increased emphasis on patient-centered outpatient management, transcutaneous monitoring has potential to recalibrate workflows by enabling continuous trending rather than episodic point measurements. Moreover, the device landscape is diversifying along axes of portability, integration, and algorithmic augmentation, which allows these tools to be tailored to specific care settings and patient risk profiles. In practice, these technological shifts are not only technical; they represent changes in clinical decision-making, procurement priorities, and training programs.

Consequently, the introduction frames the subsequent analysis by connecting technical attributes of transcutaneous monitors to operational outcomes such as reduced procedural interventions, improved trend recognition, and potential efficiencies in care delivery. The emphasis is on pragmatic deployment pathways that support adoption across a range of healthcare environments, from highly monitored intensive care units to ambulatory clinics and homecare scenarios.

How technological, regulatory, and care-delivery transformations are converging to redefine deployment and value of transcutaneous PO2 and PCO2 monitoring

The landscape for transcutaneous PO2 and PCO2 monitoring is shifting in ways that are as technological as they are structural. Advances in sensor chemistry, thinner membrane designs, and low-power wireless protocols have enabled devices that are both more accurate and more convenient to deploy. At the same time, software-driven analytics and cloud-enabled data aggregation are extending the utility of single-sensor data into longitudinal patient records and population-level insights. Together, these developments facilitate new models of care where continuous physiologic monitoring informs earlier intervention and more personalized titration of therapy.

In parallel, regulatory expectations and procurement criteria are evolving to emphasize interoperability, cybersecurity, and evidence of clinical utility. Health systems increasingly favor devices that integrate with electronic medical records and adhere to standardized data formats, creating pressure on vendors to prioritize open architectures. Furthermore, reimbursement landscapes and clinical pathways are adapting to favor noninvasive modalities that reduce procedural burden; this is accelerating interest in transcutaneous solutions that can demonstrably lower the frequency of arterial sampling while maintaining diagnostic confidence.

Additionally, workforce dynamics and care-site diversification are important catalysts for change. Staffing shortages and shifts toward ambulatory and home-based care are prompting clinical teams to seek monitoring technologies that support task-shifting and remote supervision. Consequently, the market is moving toward modular product designs, flexible service models, and partnerships that embed monitoring capabilities into broader digital health ecosystems. These transformative shifts highlight a trajectory where clinical value, data integration, and operational flexibility converge to redefine the role of transcutaneous monitoring in contemporary care delivery.

Assessment of how the 2025 United States tariff measures reshaped supply chains, sourcing strategies, and product design priorities across transcutaneous monitoring suppliers

Tariff policy changes enacted in the United States in 2025 have exerted a multifaceted influence on the transcutaneous monitoring supply chain and commercial strategies. Importantly, tariffs affect the economics of sourcing sensor components, electronic modules, and finished devices, prompting manufacturers and health system procurement teams to reassess supplier footprints. As a result, some vendors have accelerated diversification of their supplier base and increased investment in nearshore production capabilities to mitigate tariff exposure and compress lead times.

At the same time, higher import costs have incentivized product rationalization and modular design approaches that reduce reliance on tariff-exposed components. Vendors are prioritizing local assembly of subassemblies and reconfigurable platforms that can be tailored to regional regulatory requirements without reinventing core technology. For healthcare providers, these supply chain adjustments have manifested as sporadic price adjustments, longer qualification lead times for new suppliers, and an elevated emphasis on total cost of ownership during procurement deliberations.

Moreover, tariffs have amplified the importance of regulatory agility and supply chain transparency. Organizations are placing greater emphasis on traceability, dual-sourcing strategies, and contractual clauses that allocate currency and trade risk. Consequently, strategic alliances and contract manufacturing relationships have taken on new relevance as pathways to preserve margin and ensure continuity of supply. In sum, the cumulative effect of tariff actions has been to accelerate risk mitigation efforts, to shift some sourcing toward regional partners, and to catalyze design decisions that reduce trade exposure while maintaining clinical performance.

Insights into how product types, portability, mounting options, and end-user environments drive differentiated requirements and adoption pathways for transcutaneous monitors

Segmentation analysis reveals how divergent clinical needs and deployment contexts shape product development and commercialization priorities for transcutaneous PO2 and PCO2 monitoring. Based on product type, the landscape includes Combined Monitor solutions that integrate dual-gas sensing, PCO2-focused devices optimized for carbon dioxide trends, and PO2-dedicated systems tuned for oxygen assessment. These distinctions influence calibration strategies, sensor membrane selection, and user-interface features that clinicians favor in different care scenarios.

Turning to portability, the market is studied across Portable devices that support point-of-care flexibility and Stationary platforms intended for continuous bedside monitoring. Portability considerations drive battery management, wireless connectivity choices, and wearable ergonomics, whereas stationary systems prioritize integration with bedside infrastructure and advanced alarm workflows. Equally, mounting type differentiates between Benchtop instruments suited to clinical workstation environments and Wall Mounted configurations designed to conserve surface space and centralize monitoring in high-acuity units.

End user segmentation further clarifies clinical adoption pathways. The market is examined across Clinic settings where ambulatory surgical centers and physician offices demand compact, user-friendly devices; Homecare contexts that require simplified interfaces, extended sensor life, and robust remote connectivity; and Hospital environments where emergency departments, intensive care units, neonatal intensive care units, and operating rooms demand high-fidelity measurements, rapid calibration, and seamless integration with existing monitoring systems. Through these segmentation lenses, developers and purchasers can align product roadmaps, training programs, and service models with specific clinical workflows and user expectations.

A nuanced regional view that explains how Americas, Europe Middle East & Africa, and Asia-Pacific markets demand bespoke strategies for adoption, distribution, and support

Regional dynamics play a decisive role in shaping product demand, regulatory strategy, and go-to-market approaches for transcutaneous PO2 and PCO2 monitoring. Across the Americas, many health systems emphasize value-based procurement and rapid adoption of technologies that demonstrably reduce invasive procedures; this environment favors devices that can integrate with broad health IT ecosystems and that provide robust clinical evidence for utility. Regulatory frameworks in key national markets also create consistent pathways for clinical validation and hospital adoption, encouraging partnerships between vendors and large integrated delivery networks.

In Europe, Middle East & Africa, fragmentation in regulatory regimes and heterogeneous procurement practices result in a mosaic of adoption patterns. Some markets prioritize cost-containment and local manufacturing partnerships, while others emphasize advanced clinical capabilities and interoperability. Consequently, vendors often deploy region-specific strategies that combine direct sales in high-income European markets with distributor partnerships and localized service models in other parts of the region. This tiered approach enables alignment with variable reimbursement environments and infrastructural maturity.

Asia-Pacific is characterized by rapid technological uptake in several advanced healthcare systems alongside a growing number of emerging markets seeking scalable, low-cost monitoring solutions. In many countries, the confluence of expanding neonatal care capacity and investment in acute care facilities creates demand for both portable and stationary transcutaneous systems. Vendors targeting this region benefit from flexible pricing models, local manufacturing partnerships, and regulatory strategies that accommodate accelerated evaluation while ensuring adherence to international performance standards. Collectively, these regional nuances inform prioritization of product development, distribution networks, and post-sale support models.

How competitive positioning is evolving through clinical validation, integrated service models, and data-driven differentiation among transcutaneous monitoring vendors

Competitive dynamics within the transcutaneous monitoring space are shaped by a mix of established medical device manufacturers, specialized sensor developers, and emerging digital-health entrants. Leading players differentiate through depth of clinical validation, strength of distribution networks, and the ability to integrate monitoring data into broader care management systems. Some companies have prioritized vertical integration-controlling sensor chemistry, electronics, and software-to optimize performance and to protect intellectual property, while others have formed strategic partnerships or licensing agreements to accelerate market entry and extend their product portfolios.

In addition to product features, service models and lifecycle support increasingly determine competitive advantage. Organizations that offer modular maintenance contracts, on-site training, and remote calibration services reduce operational friction for hospitals and clinics, thereby improving user retention. Furthermore, companies that invest in interoperability and secure data-sharing capabilities position themselves favorably as healthcare organizations look to consolidate monitoring data into enterprise analytics platforms.

Finally, new entrants applying artificial intelligence and predictive analytics to monitoring streams are reshaping expectations about what continuous physiological data can deliver. These capabilities enhance early warning systems and clinical decision support, creating additional differentiation beyond hardware specifications. As a result, collaboration between device makers, software vendors, and care providers has become central to competitive strategy, and market leadership increasingly depends on the ability to deliver validated clinical outcomes rather than hardware alone.

Practical strategic actions for manufacturers and health systems to accelerate adoption, de-risk supply chains, and demonstrate clinical and economic value

Industry leaders seeking to accelerate adoption and to protect commercial margins should align product development, regulatory planning, and commercial models with real-world clinical workflows. First, prioritize interoperability and user-centered design to ensure devices can be incorporated into diverse electronic health record environments and that clinicians can deploy them with minimal training. Investments in standards-based communication protocols and streamlined user interfaces reduce implementation friction and support faster clinician acceptance.

Second, develop flexible manufacturing and supply chain strategies that mitigate trade exposure and enable rapid scaling. Nearshoring assembly of critical subcomponents, qualifying multiple suppliers for sensor membranes and electronic modules, and negotiating resilient service contracts will reduce operational risk. Third, frame value propositions around clinical outcomes and total cost of care rather than unit price alone. Collaborative pilot studies with high-volume neonatal and critical care centers can generate the evidence needed to support procurement decisions and payer conversations.

Finally, embrace service-led commercialization models that incorporate remote calibration, predictive maintenance, and outcome analytics into recurring revenue streams. These models not only strengthen customer relationships but also provide ongoing data that can inform iterative product improvements. By pursuing these actions in a coordinated manner, leaders can translate technological capability into durable market presence and measurable improvements in patient care.

A transparent, multi-method research approach combining clinician interviews, supplier assessments, and regulatory analysis to produce validated and actionable insights

The research underpinning this analysis combines primary stakeholder engagement with structured secondary review to ensure rigorous, actionable conclusions. Primary inputs include in-depth interviews with clinicians across neonatal, intensive care, emergency, and perioperative specialties, procurement leaders from diverse health system types, and executives from device manufacturers and component suppliers. These conversations were designed to surface real-world deployment challenges, clinical priorities, and procurement decision criteria, and they informed interpretation of technical trends and competitive dynamics.

Secondary analysis integrated regulatory guidance documents, device performance literature, and credible policy reporting to contextualize operational and supply chain developments. In addition, comparative device feature mapping and supplier capability assessments were performed to identify differentiators across product portfolios. The methodology emphasizes triangulation: thematic insights derived from interviews were cross-checked against secondary sources and supplier disclosures to validate claims and to refine recommendations.

Throughout the process, attention was paid to minimizing bias through balanced sampling across geographies and end-user types, and by documenting assumptions that underpin interpretive judgments. The resulting framework supports both strategic planning and tactical decision-making by highlighting where clinical needs intersect with technological possibilities and commercial realities.

A concise synthesis that ties technological advances, supply chain realities, and clinical priorities into strategic conclusions for stakeholders in transcutaneous monitoring

In conclusion, transcutaneous PO2 and PCO2 monitoring occupies an increasingly important niche within contemporary respiratory and critical care practice. Technological refinements, enhanced data integration, and service-oriented commercialization approaches are expanding the contexts in which these devices can add clinical value. At the same time, supply chain pressures and evolving regulatory expectations compel vendors and purchasers to adopt resilient sourcing strategies and to prioritize interoperable, user-centered solutions.

Looking ahead, stakeholders that align product design with demonstrable clinical outcomes and that adopt flexible commercial models will be best positioned to capture opportunities across neonatal care, intensive care, ambulatory settings, and homecare. Strategic partnerships that marry hardware expertise with analytics and integration capabilities will further accelerate adoption by simplifying implementation for busy clinical teams. Ultimately, the most impactful advances will be those that translate continuous physiologic data into clearer, earlier clinical decisions and measurable improvements in patient experience.

This synthesis is intended to inform leaders across clinical, commercial, and regulatory functions as they define roadmaps, prioritize investments, and negotiate procurement strategies in a rapidly evolving landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcutaneous PO2 & PCO2 Monitor Market, by Product Type

  • 8.1. Combined Monitor
  • 8.2. PCO2 Monitor
  • 8.3. PO2 Monitor

9. Transcutaneous PO2 & PCO2 Monitor Market, by Portability

  • 9.1. Portable
  • 9.2. Stationary

10. Transcutaneous PO2 & PCO2 Monitor Market, by Mounting Type

  • 10.1. Benchtop
  • 10.2. Wall Mounted

11. Transcutaneous PO2 & PCO2 Monitor Market, by End User

  • 11.1. Clinic
    • 11.1.1. Ambulatory Surgical Center
    • 11.1.2. Physician Office
  • 11.2. Homecare
  • 11.3. Hospital
    • 11.3.1. Emergency Department
    • 11.3.2. Intensive Care Unit
    • 11.3.3. Neonatal Intensive Care Unit
    • 11.3.4. Operating Room

12. Transcutaneous PO2 & PCO2 Monitor Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transcutaneous PO2 & PCO2 Monitor Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transcutaneous PO2 & PCO2 Monitor Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transcutaneous PO2 & PCO2 Monitor Market

16. China Transcutaneous PO2 & PCO2 Monitor Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bionet Co., Ltd.
  • 17.6. Contec Medical Systems Co., Ltd.
  • 17.7. Criticare Systems, Inc.
  • 17.8. Dragerwerk AG & Co. KGaA
  • 17.9. Edan Instruments, Inc.
  • 17.10. Edwards Lifesciences Corporation
  • 17.11. GE Healthcare Ltd.
  • 17.12. Masimo Corporation
  • 17.13. Medtronic plc
  • 17.14. Mindray Medical International Limited
  • 17.15. Natus Medical Incorporated
  • 17.16. NIHON KOHDEN Corporation
  • 17.17. Nonin Medical, Inc.
  • 17.18. OSENSA Innovations, Inc.
  • 17.19. Oximetrix, Inc.
  • 17.20. Philips Healthcare
  • 17.21. PULSION Medical Systems SE
  • 17.22. Radiometer Medical ApS
  • 17.23. SenTec AG
  • 17.24. SLE Limited
  • 17.25. Smiths Medical, Inc.
  • 17.26. Spacelabs Healthcare, Inc.
  • 17.27. Toshiba Medical Systems Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COMBINED MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COMBINED MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COMBINED MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PCO2 MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PCO2 MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PCO2 MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PO2 MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PO2 MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PO2 MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY STATIONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY STATIONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY STATIONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY WALL MOUNTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY WALL MOUNTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY WALL MOUNTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PHYSICIAN OFFICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PHYSICIAN OFFICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PHYSICIAN OFFICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY NEONATAL INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY NEONATAL INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY NEONATAL INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY OPERATING ROOM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY OPERATING ROOM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY OPERATING ROOM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 124. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 127. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 148. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 152. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 155. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)